<p>Galectin Therapeutics（納斯達克代碼：GALT - 獲取免費報告）預計將在 2025 年第二季度市場開盤前於 8 月 12 日（星期二）公佈其財報。分析師預計該公司本季度每股收益為（$0.16）。</p>
<p>Galectin Therapeutics（納斯達克代碼：GALT - 獲取免費報告）上一次發佈財報是在 5 月 15 日（星期四）。該公司報告本季度每股收益為（$0.15），超出市場共識預期的（$0.20）$0.05。分析師平均預計 Galectin Therapeutics 在當前財年每股收益為$-1，在下一個財年每股收益也為$-1。</p>
<p>獲取 <strong>Galectin Therapeutics</strong> 的提醒：</p>
<h2>Galectin Therapeutics 股價下跌 1.1%</h2>
<p>GALT 股票在週二交易中下跌$0.04，報$3.55。該公司股票交易量為 32,857 股，而其平均交易量為 420,276 股。該公司的 50 日移動平均價格為$2.30，200 日移動平均價格為$1.71。該股票的市值為 2.2469 億美元，市盈率為-4.93，貝塔值為 0.81。Galectin Therapeutics 的 52 周低點為$0.73，52 周高點為$3.90。</p>
<h2>分析師評級變動</h2>
<p>幾位研究分析師對 GALT 股票發表了評論。華爾街 Zen 在 6 月 21 日（星期六）的一份研究報告中將 Galectin Therapeutics 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 6 月 17 日（星期二）開始對 Galectin Therapeutics 進行覆蓋。他們對該股票設定了 “買入” 評級和$6.00 的目標價。</p>
<p><strong>獲取我們最新的 GALT 股票報告</strong></p>
<h2>機構資金流入和流出</h2>
<p>一家對沖基金最近增加了對 Galectin Therapeutics 股票的持股。根據該公司最近向證券交易委員會的披露，美國銀行（Bank of America Corp DE）在第四季度將其在 Galectin Therapeutics Inc.（納斯達克代碼：GALT - 免費報告）的持股增加了 101.4%。該公司在此期間購買了額外的 19,316 股後，持有 38,358 股。美國銀行（Bank of America Corp DE）在最近的報告期末持有約 0.06% 的 Galectin Therapeutics，價值$49,000。目前，11.68% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Galectin Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Galectin Therapeutics Inc 是一家臨牀階段的生物製藥公司，專注於纖維化、癌症及其他疾病的治療研究與開發。其主要產品候選藥物是 belapectin（GR-MD-02）galectin-3 抑制劑，目前正在進行針對非酒精性脂肪性肝炎（NASH）肝硬化患者預防食管靜脈曲張的 2b/3 期臨牀試驗；以及針對肝纖維化、嚴重皮膚病、黑色素瘤和頭頸部鱗狀細胞癌的 2 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Galectin Therapeutics 更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>Figma 的瘋狂 IPO 之旅：股票的溢價價格是否合理？</li>
<li>股票股息削減發生，你準備好了嗎？</li>
<li>META 獲得巨大升級：分析師認為股票可能上漲多高</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>諾和諾德股票下跌——但底部是否終於到來？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Galectin Therapeutics 嗎？</h2>
<p>在考慮 Galectin Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Galectin Therapeutics 並不在名單上。</p>
<p>雖然 Galectin Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Galectin治療

<p>Galectin Therapeutics（納斯達克代碼：GALT）將於 8 月 12 日公佈 2025 年第二季度財報，分析師預計每股虧損 0.16 美元。該公司此前報告每股虧損 0.15 美元，超出預期。GALT 股票最近下跌 1.1%，報 3.55 美元，市值為 2.2469 億美元。機構持股比例為 11.68%。分析師已將 GALT 的評級從 “賣出” 上調至 “持有”，並設定目標價為 6.00 美元。Galectin 專注於纖維化和癌症相關疾病的治療，其主要產品正在進行臨牀試驗</p>

<p>Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.</p>
<div class="lb-trans"><p>Galectin Therapeutics（納斯達克代碼：GALT - 獲取免費報告）預計將在 2025 年第二季度市場開盤前於 8 月 12 日（星期二）公佈其財報。分析師預計該公司本季度每股收益為（$0.16）。</p>
</div><p>Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Galectin Therapeutics（納斯達克代碼：GALT - 獲取免費報告）上一次發佈財報是在 5 月 15 日（星期四）。該公司報告本季度每股收益為（$0.15），超出市場共識預期的（$0.20）$0.05。分析師平均預計 Galectin Therapeutics 在當前財年每股收益為$-1，在下一個財年每股收益也為$-1。</p>
</div><p>Get <strong>Galectin Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Galectin Therapeutics</strong> 的提醒：</p>
</div><h2>Galectin Therapeutics Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Galectin Therapeutics 股價下跌 1.1%</h2>
</div><p>GALT stock traded down $0.04 during trading on Tuesday, hitting $3.55. 32,857 shares of the company's stock were exchanged, compared to its average volume of 420,276. The business has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $1.71. The stock has a market capitalization of $224.69 million, a price-to-earnings ratio of -4.93 and a beta of 0.81. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.90.</p>
<div class="lb-trans"><p>GALT 股票在週二交易中下跌$0.04，報$3.55。該公司股票交易量為 32,857 股，而其平均交易量為 420,276 股。該公司的 50 日移動平均價格為$2.30，200 日移動平均價格為$1.71。該股票的市值為 2.2469 億美元，市盈率為-4.93，貝塔值為 0.81。Galectin Therapeutics 的 52 周低點為$0.73，52 周高點為$3.90。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research analysts have commented on GALT shares. Wall Street Zen raised Galectin Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, June 21st. HC Wainwright started coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a &#34;buy&#34; rating and a $6.00 price target on the stock.</p>
<div class="lb-trans"><p>幾位研究分析師對 GALT 股票發表了評論。華爾街 Zen 在 6 月 21 日（星期六）的一份研究報告中將 Galectin Therapeutics 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 6 月 17 日（星期二）開始對 Galectin Therapeutics 進行覆蓋。他們對該股票設定了 “買入” 評級和$6.00 的目標價。</p>
</div><p><strong>Get Our Latest Stock Report on GALT</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 GALT 股票報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned approximately 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent reporting period. 11.68% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對 Galectin Therapeutics 股票的持股。根據該公司最近向證券交易委員會的披露，美國銀行（Bank of America Corp DE）在第四季度將其在 Galectin Therapeutics Inc.（納斯達克代碼：GALT - 免費報告）的持股增加了 101.4%。該公司在此期間購買了額外的 19,316 股後，持有 38,358 股。美國銀行（Bank of America Corp DE）在最近的報告期末持有約 0.06% 的 Galectin Therapeutics，價值$49,000。目前，11.68% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Galectin Therapeutics</h2>
<div class="lb-trans"><h2>關於 Galectin Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.</p>
<div class="lb-trans"><p>Galectin Therapeutics Inc 是一家臨牀階段的生物製藥公司，專注於纖維化、癌症及其他疾病的治療研究與開發。其主要產品候選藥物是 belapectin（GR-MD-02）galectin-3 抑制劑，目前正在進行針對非酒精性脂肪性肝炎（NASH）肝硬化患者預防食管靜脈曲張的 2b/3 期臨牀試驗；以及針對肝纖維化、嚴重皮膚病、黑色素瘤和頭頸部鱗狀細胞癌的 2 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Galectin Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>META Gets Huge Upgrades: How High Analysts Think Shares Could Go</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Galectin Therapeutics 更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>Figma 的瘋狂 IPO 之旅：股票的溢價價格是否合理？</li>
<li>股票股息削減發生，你準備好了嗎？</li>
<li>META 獲得巨大升級：分析師認為股票可能上漲多高</li>
<li>如何投資科技股以及值得考慮的頂級科技股</li>
<li>諾和諾德股票下跌——但底部是否終於到來？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=GALT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Galectin Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Galectin Therapeutics 嗎？</h2>
</div><p>Before you consider Galectin Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Galectin Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Galectin Therapeutics 並不在名單上。</p>
</div><p>While Galectin Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Galectin Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Galectin 治療公司（GALT）預計將在週二宣佈季度財報